Jasmine H Francis1, Brian P Marr2, David H Abramson2. 1. Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical Center, New York, New York. Electronic address: francij1@mskcc.org. 2. Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical Center, New York, New York.
Abstract
PURPOSE: To evaluate the patient, disease, and tumor characteristics of the 3 morphologically distinct groups of vitreous seeds in retinoblastoma presenting for treatment with ophthalmic artery chemosurgery (OAC): dust (class 1), spheres (class 2), and clouds (class 3) in primary and recurrent vitreous seeds. DESIGN: Retrospective cohort study of patients treated for vitreous seeds at Memorial Sloan Kettering Cancer Center between May 2006 and March 2015. PARTICIPANTS: A total of 135 eyes with active vitreous seeds, presenting for primary treatment with OAC or with recurrent vitreous disease. METHODS: Vitreous seeds were classified into 3 groups: dust, spheres, and clouds. Indirect ophthalmoscopy, fundus photography, ultrasonography, and ultrasonic biomicroscopy were used to locate and evaluate the extent of retinal and vitreous disease. Patient and disease characteristics (age, laterality of disease, treatment status) were compared among classification groups. A 2-tailed Fisher exact test and paired Student t test were used for statistical analysis. MAIN OUTCOME MEASURES: Age of patient, laterality of disease, location of retinal disease, extent of vitreous disease, and treatment status. RESULTS: Primary treated disease: Patients with eyes containing class 3 (cloud) vitreous seeds were significantly older than patients with class 1 or 2 seeds (P < 0.05). The median age of patients with class 1, 2, and 3 seeds was 11, 15.5, and 32 months, respectively. Eyes containing class 3 seeds were significantly more likely to occur in the equator-ora region of the fundus (P < 0.0001), in a diffuse pattern (P < 0.0001), and in patients with unilateral disease (P < 0.05), compared with class 1 and 2 seeds. Recurrent disease: Recurrent vitreous seeds were significantly more common to class 2 (P < 0.05), occurring in a diffuse pattern (P = 0.01) and in patients with bilateral disease (P < 0.001). CONCLUSIONS: The 3 classes of vitreous seeds have distinct clinical characteristics associated with the age of patient, laterality of disease, and extent and location of tumor-producing seeds. Furthermore, recurrent vitreous seeds appear to have a unique clinical profile compared with seeds receiving primary treatment.
PURPOSE: To evaluate the patient, disease, and tumor characteristics of the 3 morphologically distinct groups of vitreous seeds in retinoblastoma presenting for treatment with ophthalmic artery chemosurgery (OAC): dust (class 1), spheres (class 2), and clouds (class 3) in primary and recurrent vitreous seeds. DESIGN: Retrospective cohort study of patients treated for vitreous seeds at Memorial Sloan Kettering Cancer Center between May 2006 and March 2015. PARTICIPANTS: A total of 135 eyes with active vitreous seeds, presenting for primary treatment with OAC or with recurrent vitreous disease. METHODS: Vitreous seeds were classified into 3 groups: dust, spheres, and clouds. Indirect ophthalmoscopy, fundus photography, ultrasonography, and ultrasonic biomicroscopy were used to locate and evaluate the extent of retinal and vitreous disease. Patient and disease characteristics (age, laterality of disease, treatment status) were compared among classification groups. A 2-tailed Fisher exact test and paired Student t test were used for statistical analysis. MAIN OUTCOME MEASURES: Age of patient, laterality of disease, location of retinal disease, extent of vitreous disease, and treatment status. RESULTS: Primary treated disease: Patients with eyes containing class 3 (cloud) vitreous seeds were significantly older than patients with class 1 or 2 seeds (P < 0.05). The median age of patients with class 1, 2, and 3 seeds was 11, 15.5, and 32 months, respectively. Eyes containing class 3 seeds were significantly more likely to occur in the equator-ora region of the fundus (P < 0.0001), in a diffuse pattern (P < 0.0001), and in patients with unilateral disease (P < 0.05), compared with class 1 and 2 seeds. Recurrent disease: Recurrent vitreous seeds were significantly more common to class 2 (P < 0.05), occurring in a diffuse pattern (P = 0.01) and in patients with bilateral disease (P < 0.001). CONCLUSIONS: The 3 classes of vitreous seeds have distinct clinical characteristics associated with the age of patient, laterality of disease, and extent and location of tumor-producing seeds. Furthermore, recurrent vitreous seeds appear to have a unique clinical profile compared with seeds receiving primary treatment.
Authors: Jesse L Berry; Rima Jubran; Jonathan W Kim; Kenneth Wong; Simon R Bababeygy; Hashem Almarzouki; Thomas C Lee; A Linn Murphree Journal: Pediatr Blood Cancer Date: 2012-09-19 Impact factor: 3.167
Authors: Jasmine H Francis; David H Abramson; Marie-Claire Gaillard; Brian P Marr; Maja Beck-Popovic; Francis L Munier Journal: Ophthalmology Date: 2015-03-18 Impact factor: 12.079
Authors: Carol L Shields; Alexzandra M Douglass; Meriem Beggache; Emil Anthony T Say; Jerry A Shields Journal: Retina Date: 2016-06 Impact factor: 4.256
Authors: Jesse L Berry; Liya Xu; Irsan Kooi; A Linn Murphree; Rishvanth K Prabakar; Mark Reid; Kevin Stachelek; Bao Han A Le; Lisa Welter; Bibiana J Reiser; Patricia Chévez-Barrios; Rima Jubran; Thomas C Lee; Jonathan W Kim; Peter Kuhn; David Cobrinik; James Hicks Journal: Mol Cancer Res Date: 2018-07-30 Impact factor: 5.852
Authors: Lauren A Dalvin; Mamta Kumari; Vera Adobea Essuman; Shormin Shohelly Shipa; David Ancona-Lezama; J Antonio Lucio-Alvarez; Pascal Jabbour; Carol L Shields Journal: Ocul Oncol Pathol Date: 2018-08-21
Authors: Paula Schaiquevich; Jasmine H Francis; María Belén Cancela; Angel Montero Carcaboso; Guillermo L Chantada; David H Abramson Journal: Front Oncol Date: 2022-04-01 Impact factor: 5.738
Authors: Michelle G Zhang; Jeffim N Kuznetsoff; Dawn A Owens; Ryan A Gallo; Karthik Kalahasty; Anthony M Cruz; Stefan Kurtenbach; Zelia M Correa; Daniel Pelaez; J William Harbour Journal: Cancers (Basel) Date: 2022-10-10 Impact factor: 6.575
Authors: Ankit Singh Tomar; Paul T Finger; Brenda Gallie; Tero Kivelä; Ashwin Mallipatna; Chengyue Zhang; Junyang Zhao; Matthew Wilson; Rachel Brennan; Michala Burges; Jonathan Kim; Jesse L Berry; Rima Jubran; Vikas Khetan; Suganeswari Ganeshan; Andrey Yarovoy; Vera Yarovaya; Elena Kotova; Denis Volodin; Yacoub Yousef; Kalle Nummi; Tatiana L Ushakova; Olga V Yugay; Vladimir G Polyakov; Marco Antonio Ramirez-Ortiz; Elizabeth Esparza-Aguiar; Guillermo L Chantada; Paula Schaiquevich; Adriana C Fandiño; Jason C Yam; Winnie W Lau; Carol P Lam; Phillipa Sharwood; Sonia Moorthy; Quah Boon Long; Vera Adobea Essuman; Lorna A Renner; Ekaterina Semenova; Jaume Català-Mora; Maria Correa Llano; Elisa Carreras Journal: Br J Ophthalmol Date: 2021-08-02 Impact factor: 5.908